Here are the top 5 biosimilar articles for the week of January 31, 2022.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of January 31, 2022.
Number 5: Two new studies investigated Imraldi (SB5), an adalimumab biosimilar developed by Samsung Bioepis, in inflammatory bowel disease (IBD).
Number 4: The Biosimilars Forum has appointed Cofounder and President Juliana (Julie) M. Reed, as the new executive director. Reed shared some of her goals for the Biosimilars Forum in an interview with The Center for Biosimilars®.
Number 3: After increasing its ownership stake in Samsung Bioepis from 15% to 50% in 2018, Biogen is now selling it for up to $2.3 billion.
Number 2: Three studies from the Indian Institute of Technology in Delhi laid out the biosimilar approval guidelines and market growth projections for several countries in the Asia Pacific region, Latin America, the Middle East and Africa.
Number 1: US biosimilar uptake faces several barriers, including misconceptions regarding biosimilar efficacy and a misalignment of prescription incentives between payers, providers, and patients, panelists discussed.
To read all of these articles and more, visit centerforbiosimilars.com.
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD
February 15th 2025Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
February 9th 2025In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.